Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent.

Major advances in cancer biology and immunology have been gained using mouse models. However, very few methods are currently available to visualize the deep lymphatic system. A new micro-magnetic resonance lymphangiography (MRL) method in mice, which uses dendrimer-based magnetic resonance imaging contrast agents, was developed. Micro-MRL imaging clearly visualized most of the mouse lymphatic system, including both lymphatics and lymph nodes. This method could detect and distinguish among dilation of lymphatic vessels in a lymphangitis model, proliferative or neoplastic lymph node swellings in a lymphoproliferative model, and inflammatory lymph node swellings in an infection/inflammation model. Changes in the lymphoid system of transgenic mice overexpressing interleukin-15 could be visualized. Abnormal enlarged lymph nodes identified by micro-MRL were selectively removed and analyzed to demonstrate their cell type, receptor expression, and clonality in individual mice. We conclude that the enhanced resolution of this noninvasive micro-MRL can detect and classify lymphatic and lymph node abnormalities in mice, which should have wide applicability to the study of immunology and cancer in both experimental animals and clinical medicine.

[1]  Hisataka Kobayashi,et al.  Scintigraphic detection of neural-cell-derived small-cell lung cancer using glioma-specific antibody , 2005, Journal of Cancer Research and Clinical Oncology.

[2]  Rakesh K Jain,et al.  Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.

[3]  R. Günther,et al.  T1-weighted MR-lymphography after intramammary administration of Gadomer-17 in pigs. , 2002, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[4]  M. Brechbiel,et al.  Micro‐MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer‐based MR contrast agents , 2001, Journal of magnetic resonance imaging : JMRI.

[5]  M. Brechbiel,et al.  Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores , 2001, Magnetic resonance in medicine.

[6]  Akira Hiraga,et al.  Novel liver macromolecular MR contrast agent with a polypropylenimine diaminobutyl dendrimer core: Comparison to the vascular MR contrast agent with the polyamidoamine dendrimer core , 2001, Magnetic resonance in medicine.

[7]  M. Brechbiel,et al.  Dynamic micro-magnetic resonance imaging of liver micrometastasis in mice with a novel liver macromolecular magnetic resonance contrast agent DAB-Am64-(1B4M-Gd)(64). , 2001, Cancer research.

[8]  M. Brechbiel,et al.  3D‐micro‐MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties , 2001, Magnetic resonance in medicine.

[9]  M. Brechbiel,et al.  Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer. , 2001, Bioconjugate chemistry.

[10]  G. Frija,et al.  MR lymphography using iron oxide nanoparticles in rats: Pharmacokinetics in the lymphatic system after intravenous injection , 2000, Journal of magnetic resonance imaging : JMRI.

[11]  T. Waldmann,et al.  IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[13]  Magnetic resonance lymphography of profundus lymph nodes with liposomal gadolinium-diethylenetriamine pentaacetic acid. , 2000, Biological & pharmaceutical bulletin.

[14]  P. Bruehlmann,et al.  Lymphatic microangiopathy of the skin in systemic sclerosis. , 1999, Rheumatology.

[15]  M. Brechbiel,et al.  Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. , 1999, Bioconjugate chemistry.

[16]  R. Jain,et al.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.

[17]  Perrymore Wd,et al.  Technetium-99m-Albumin Colloid Lymphoscintigraphy in Postoperative Lymphocele , 1996 .

[18]  B. Hamm,et al.  Magnetic resonance lymphography in rats: effects of muscular activity and hyperthermia on the lymph node uptake of intravenously injected superparamagnetic iron oxide particles. , 1996, Academic radiology.

[19]  N. Hylton,et al.  Evaluation of the effects of intravascular MR contrast media (gadolinium dendrimer) on 3D time of flight magnetic resonance angiography of the body , 1996, Journal of magnetic resonance imaging : JMRI.

[20]  R K Jain,et al.  Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory. , 1996, The American journal of physiology.

[21]  R K Jain,et al.  Transport in lymphatic capillaries. II. Microscopic velocity measurement with fluorescence photobleaching. , 1996, The American journal of physiology.

[22]  J. Harolds,et al.  Technetium-99m-albumin colloid lymphoscintigraphy in postoperative lymphocele. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  R. Castellino,et al.  Characterization of Reactive Versus Tumor-Bearing Lymph Nodes with Interstitial Magnetic Resonance Lymphography in an Animal Model , 1995, Investigative radiology.

[24]  R. Weissleder,et al.  MR Lymphography with a Lymphotropic T1‐Type MR Contrast Agent: Gd‐DTPA‐PGM , 1995, Magnetic resonance in medicine.

[25]  R K Jain,et al.  Flow velocity in the superficial lymphatic network of the mouse tail. , 1994, The American journal of physiology.

[26]  P. Singh,et al.  Starburst dendrimers: enhanced performance and flexibility for immunoassays. , 1994, Clinical chemistry.

[27]  R Weissleder,et al.  MR lymphography: study of a high-efficiency lymphotrophic agent. , 1994, Radiology.

[28]  Martin W. Brechbiel,et al.  Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging , 1994 .

[29]  P C Lauterbur,et al.  Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents , 1994, Magnetic resonance in medicine.

[30]  R. Barth,et al.  Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. , 1994, Bioconjugate chemistry.

[31]  M. Taupitz,et al.  Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits. , 1993, AJR. American journal of roentgenology.

[32]  A. Darkazanli,et al.  MR lymphography with iron oxide compound AMI-227: studies in ferrets with filariasis. , 1992, AJR. American journal of roentgenology.

[33]  J. Bertrand,et al.  Anaphylactic shock induced by intravenous gadopentetate dimeglumine , 1992, The Lancet.

[34]  B. Hamm,et al.  MR lymphography with iron oxide particles: dose-response studies and pulse sequence optimization in rabbits. , 1992, AJR. American journal of roentgenology.

[35]  H. Abdel-Dayem,et al.  Tc-99m Human Serum Albumin Lymphoscintigraphy in Lymphedema of the Lower Extremities , 1990, Clinical nuclear medicine.

[36]  William A. Goddard,et al.  Starburst Dendrimers: Molecular‐Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter , 1990 .

[37]  R. Silvestri,et al.  Respiratory distress syndrome from lymphangiography contrast medium. , 1980, The American review of respiratory disease.